Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda has agreed to pay AC Immune $100 million upfront and up to $2.1 billion in milestones for an option to license an experimental Alzheimer's vaccine, as…
Takeda is returning to Alzheimer's research with an option and licensing deal worth up to $2.2 billion for AC Immune's amyloid vaccine. The bet is on an active…
AC Immune Form 6-K (filed 2026-04-30) reporting Q1 2026 update: dosing of first patients in final ABATE Cohort AD4 triggered a $12 million milestone under the…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
In May 2024 Takeda and AC Immune (Nasdaq: ACIU) signed an exclusive worldwide option and license agreement for AC Immune's anti-amyloid-beta active immunotherapy portfolio, led by ACI-24.060 in the Phase 1b/2 ABATE study in prodromal Alzheimer's disease and in adults with Down syndrome-associated AD. AC Immune received $100M upfront and is eligible for an option-exercise fee plus development, commercial and sales milestones of up to ~$2.1B (~$2.2B total), plus tiered double-digit royalties. As of mid-2026 the deal remains in its pre-option phase: Takeda has not yet exercised its option, and AC Immune is still conducting and funding the ABATE trial. On April 30, 2026, AC Immune triggered a $12M Takeda milestone by dosing the first patients in the final ABATE Cohort AD4 (36 prodromal-AD patients, 12-month treatment + 6-month follow-up). The pivotal near-term catalyst is the 12-month interim readout from Cohorts AD1/AD2/AD3 (74 patients) expected in Q2 2026, which is expected to inform Takeda's option-exercise decision. Upon exercise, Takeda would conduct and fund all further development and own global regulatory and commercialization rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / AC Immune SA (this deal) | 2024 | $2.2B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · Takeda Pharmaceutical Company Ltd. deals · Neurology deals